A Patient-Centered Approach to Achieve Remission in Ulcerative Colitis
Symposium Date: Saturday, December 6, 2014Hilton Orlando - 6001 Destination Pkwy, Orlando, FL 32819, USA
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, December 6, 2015
Note: Credit Is No Longer Available
 | Maria T. Abreu, MD Director, Crohn's and Colitis Center Martin Kalser Chair in Gastroenterology Professor of Medicine Professor of Microbiology and Immunology University of Miami Miller School of Medicine Miami, FL |
 | Raymond K. Cross, MD, MS, AGAF Associate Professor of Medicine Division of Gastroenterology and Hepatology Director of the Inflammatory Bowel Disease Program University of Maryland School of Medicine Co-Director of the Digestive Health Center University of Maryland Medical Center Baltimore, MD |
Co-provided by
Ulcerative colitis (UC) is a chronic condition that generally results in a long-term illness with high indirect costs to the patient and to society. The treatment paradigm in UC is evolving to a long-term approach in which both symptom relief and mucosal healing are the goals. As science advances and the medical armamentarium for UC grows, the practicing clinician’s ability to influence disease outcomes is improving. The new goal of therapy needs to be clearly focused on durable remission; modifying the course of the disease; and reducing hospitalizations, surgery rates, colon cancer rates, and ultimately, disability rates. Symptomatic remission is an insufficient goal for both the clinician and patient.
Therapies are available to get patients closer to the goal of remission or to the actual goal of sustained remission; clinicians need to know how to use these medicines to the optimum in each patient, and each patient responds differently, which makes the management of IBD more challenging. The goal of this educational symposium is to increase use of strategies that will provide durable remission and to optimize treatment adherence in patients with inflammatory bowel disease (IBD).
In this live and interactive session, faculty will present the latest evidence for managing the patient with UC and also translate that evidence to clinical practice through patient cases and a live Q&A session. Through the use of interactive technology, learners will be able to ask questions directly to faculty, share perspectives, and take notes of key points on slides that will be emailed to them—all with the goal of translating the latest scientific findings from podium into the clinical practice to facilitate early, appropriate treatment for all patients with IBD to improve patient health outcomes.
This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:
Implement individualized, patient-centric, treatment plans that document a treat-to-target approach toward a goal long-term, sustained remission for patients with ulcerative colitis.
At the end of this CE activity, participants should be able to:
- Establish goals of treatment that focus not only on symptomatic relief, but strives for mucosal healing and durable remission for patients with ulcerative colitis.
- Institute an "interactive treatment plan" that includes regular participation by the patient to promote active management of their ulcerative colitis and adherence to treatment.
- Implement a well-informed treatment plan that focuses on efficacy and safety and utilizes all available agents including anti-TNF inhibitors where appropriate, to optimize the long-term treatment in patients with ulcerative colitis.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Define sustained remission as a goal of treatment for patients with ulcerative colitis.
- Evaluate ways to encourage regular participation by the patient to promote active management of their ulcerative colitis.
- Review treatment plans that focus on efficacy and safety and consider anti-TNF inhibitors where appropriate, to optimize the long-term treatment in patients with ulcerative colitis.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
This educational activity is supported by an independent medical educational grant from Shire.
Gastroenterologists and other health care professionals attending the 2014 Advances in IBD conference who treat patients with UC.
CME Credit (Physicians):
The USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
USF Health, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hour.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hour of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.1 CEUs) Universal Activity Number: 0376-0000-14-017-L01-P
Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST950 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Abreu has disclosed that she serves as a consultant to AbbVie Inc.; Ferring Pharmaceuticals; Focus Medical Communications; GSK Holding Americas, Inc.; Hospira, Inc.; Janssen Pharmaceuticals, Inc.; Mucosal Health Board; Pfizer Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. She is on the advisory board of Asana Medical, Inc. She serves on the board of directors for GI Health Foundation.
Dr. Cross has disclosed that he receives grants/research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc.. He serves as a consultant for AbbVie Inc. and Janssen Pharmaceuticals, Inc. He serves on the advisory boards of AbbVie Inc. and Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has nothing to disclose.
Gary M. Roggin, MD (content/peer reviewer) has disclosed that he is a consultant to Biogen Idec, Inc.
Frances Daniel, MPH (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Disclosures have been obtained from CME Outfitters staff: Nothing to disclose.
Planning Committee, USF Health OCPD staff members and the peer/content reviewers for this activity have no relevant financial relationships to disclose.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Shire do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement:
USF is an Equal Opportunity / Affirmative Action / Equal Access Institution. For disability accommodations contact CME Outfitters at 877.CME.PROS (877.263.7767), within five days of the event. If you have credit related queries or complaints, please contact USF Health by email, cpdsupport@health.usf.edu, call 813.224.7860, or visit www.cme.hsc.usf.edu.
USF Health and CME Outfitters reserve the right to cancel this program due to unforeseen circumstances. In the unlikely event of such cancellation, USF Health and CME Outfitters will not be responsible for travel expenses incurred by the participant.
There is no fee to participate in or claim CME/CE credit for this activity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-057-120614-90
